Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Biofrontera Q3 2026 Results: Net Loss of $6.42M, Loss Narrows

Biofrontera Inc. reported a net loss of $11.8 million for the nine months ended September 30, 2026, an improvement from the $16.2 million loss in the prior year period. Product revenues grew significantly to $31.2 million compared to $24.6 million in 2025, while the company's cash position decreased to $3.2 million as of the reporting date.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.17.0
Profit before tax-6.4-6.6
Net income-6.4-6.6
EPS (diluted, $ a share)$-0.42$-0.62

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+29.8%
Operating margin-71.6%
Source

10-Q filed with the SEC, NASDAQ: BFRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biofrontera Inc.: key numbers

Share price
$0.5700Close, Nov 16
Market cap
$10.2M
Shares outstanding
17.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biofrontera Inc.

All →
8:11 AM ET 8-K
Financial Results

Biofrontera Financial Results

Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.

Term
Q3 2026

“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera
9:30 AM ET 8-K
Regulatory Approval

Biofrontera Regulatory Approval

Biofrontera received FDA approval for its supplemental New Drug Application (sNDA) for Ameluz in combination with the BF-RhodoLED lamp series to treat superficial basal cell carcinoma. This marks the first and only photodynamic therapy approved in the U.S. for a skin cancer, significantly expanding the addressable market for the company's PDT platform.

“FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor.”

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.